Kymab, a monoclonal antibody biopharmaceutical company, has raised $40 million in a Series B financing round. Bill & Melinda Gates Foundation joined existing investor Wellcome Trust in the round; each invested $20 million. The funds will enable Kymab to maximize the potential of its Kymouse platform, which is designed to increase the diversity of human antibodies produced in response to immunization with antigens. It will also advance its pipeline of therapeutic human antibodies in areas of significant unmet medical need. Additionally, Kymab will collaborate with the Gates Foundation and its partners on vaccine antigen discovery research and development with an initial focus on malaria and HIV. Kymab previously raised $20 million of Series A funding from Wellcome Trust in 2010, valuing the company at $29 million at the time.